Daiichi Sankyo discovered this HER2-directed antibody-drug conjugate (ADC) and is co-developing and commercialising it along with AstraZeneca. It is tailored leveraging Daiichi’s DXd ADC technology.

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is ...

Springtime in Washington, D.C., is synonymous with cherry blossom season, when the thousands of cherry blossom trees gifted ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

Daiichi Sankyo used the National Cherry Blossom Festival in Washington, D.C. as a platform to raise awareness about its oncology goals.

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

Antibiotics are commonly prescribed to young children to combat conditions such as ear infections and pneumonia. But the drugs may disrupt the digestive microbiome at a significant time in a child’s ...

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction ...